Drugs / MMH-MAP
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04295681 | Dec 2019 → Feb 2023 | cognitive disorder | Materia Medica Holding | Completed | Met primary |
| Phase 3 | NCT03815292 | Oct 2018 → Jan 2020 | cognitive impairment with or without cerebellar ataxia, ischemic stroke | Materia Medica Holding | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MMH-MAP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03815292 ↗ |
| Route | Oral | “Oral administration” NCT03815292 ↗ |